StockCIK 1645469
Monopar Therapeutics (MNPR): Insider Trades and Fund Holdings
In the past 12 months, Monopar Therapeutics insiders reported 0 open-market purchases worth $0 and 5 sales worth $4.02M; 5 of the sales were reported as made under a 10b5-1 trading plan.
0Insider buys, 12 months
$0Bought by insiders, 12 months
$4.02MSold by insiders, 12 months
0Tracked funds holding
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 5, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Oct 5 | Christopher M. StarrDirector | ▼ SELL10b5-1 | $659K |
| Sep 28 | Chandler RobinsonCEO | ▼ SELL10b5-1 | $2.56M |
| Aug 27 | Kim R. TsuchimotoDirector | ▼ SELL10b5-1 | $456K |
| Aug 27 | Raymond AndersonDirector | ▼ SELL10b5-1 | $351K |
| Aug 27 | Patrice RiouxOther | ▼ SELL10b5-1 | $111 |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Christopher M. Starr | Director | 0 | $0 | 1 | $659K |
| Chandler Robinson | CEO | 0 | $0 | 1 | $2.56M |
| Kim R. Tsuchimoto | Director | 0 | $0 | 1 | $456K |
| Raymond Anderson | Director | 0 | $0 | 1 | $351K |
| Patrice Rioux | Other | 0 | $0 | 1 | $111 |
ADVERTISEMENT
320 × 100 ad slot
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →